Anatoly Varaksin
Malaria remains one of the deadliest infectious diseases globally, with an estimated 229 million cases and 409,000 deaths reported in 2019 alone. The causative agents, Plasmodium parasites, have developed resistance against commonly used antimalarial drugs, necessitating the search for novel therapeutic targets. Plasmodial transcription factors and chromatin modifiers have emerged as promising targets due to their crucial roles in gene regulation and parasite development. This article delves into the significance of these regulatory proteins and explores their potential as targets for the development of next-generation antimalarial drugs.
ఈ కథనాన్ని భాగస్వామ్యం చేయండి